Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
Saved in:
| Title: | Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? |
|---|---|
| Authors: | Liu J, Chan-Tack KM, Jadhav P, Seo S, Robertson SM, Kraft J, Singer ME, Struble KA, Arya V |
| Source: | International journal of clinical pharmacology and therapeutics [Int J Clin Pharmacol Ther] 2014 Jun; Vol. 52 (6), pp. 446-53. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Dustri-Verlag Dr. K. Feistle Country of Publication: Germany NLM ID: 9423309 Publication Model: Print Cited Medium: Print ISSN: 0946-1965 (Print) Linking ISSN: 09461965 NLM ISO Abbreviation: Int J Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 24755134 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Liu+J%22">Liu J</searchLink><br /><searchLink fieldCode="AU" term="%22Chan-Tack+KM%22">Chan-Tack KM</searchLink><br /><searchLink fieldCode="AU" term="%22Jadhav+P%22">Jadhav P</searchLink><br /><searchLink fieldCode="AU" term="%22Seo+S%22">Seo S</searchLink><br /><searchLink fieldCode="AU" term="%22Robertson+SM%22">Robertson SM</searchLink><br /><searchLink fieldCode="AU" term="%22Kraft+J%22">Kraft J</searchLink><br /><searchLink fieldCode="AU" term="%22Singer+ME%22">Singer ME</searchLink><br /><searchLink fieldCode="AU" term="%22Struble+KA%22">Struble KA</searchLink><br /><searchLink fieldCode="AU" term="%22Arya+V%22">Arya V</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229423309%22">International journal of clinical pharmacology and therapeutics</searchLink> [Int J Clin Pharmacol Ther] 2014 Jun; Vol. 52 (6), pp. 446-53. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Dustri-Verlag+Dr%2E+K%2E+Feistle%22">Dustri-Verlag Dr. K. Feistle </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9423309 <i>Publication Model: </i>Print <i>Cited Medium: </i>Print <i>ISSN: </i>0946-1965 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209461965%22">09461965 </searchLink><i>NLM ISO Abbreviation: </i>Int J Clin Pharmacol Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=24755134 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.5414/CP202079 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 446 Titles: – TitleFull: Why did the FDA approve efavirenz 800 mg when co-administered with rifampin? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Liu J – PersonEntity: Name: NameFull: Chan-Tack KM – PersonEntity: Name: NameFull: Jadhav P – PersonEntity: Name: NameFull: Seo S – PersonEntity: Name: NameFull: Robertson SM – PersonEntity: Name: NameFull: Kraft J – PersonEntity: Name: NameFull: Singer ME – PersonEntity: Name: NameFull: Struble KA – PersonEntity: Name: NameFull: Arya V IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2014 Jun Type: published Y: 2014 Identifiers: – Type: issn-print Value: 0946-1965 Numbering: – Type: volume Value: 52 – Type: issue Value: 6 Titles: – TitleFull: International journal of clinical pharmacology and therapeutics Type: main |
| ResultId | 1 |
